Introduction
In lung cancer chemotherapy, third-generation chemotherapeutic drugs (paclitaxel, docetaxel, gemcitabine, vinorelbine, and irinotecan) have been associated with signifi cant advances in survival benefi t and improvement in the quality of life, 1 with platinum-based regimens the fi rst choice. Third-generation monotherapy, as well as new drugs such as amrubicin or pemetrexate, are considered good candidates for second / third-line regimens; 2 in malignant pleural mesothelioma and invasive thymoma, several complex but effective regimens have been reported. 3, 4 Therefore, patients with advanced thoracic malignancy frequently require repeated puncture of peripheral veins for blood tests, administration of consecutive chemotherapeutic agents, fl uid administration, and occasionally parenteral nutrition over a long period of time.
During repeated puncture of peripheral veins, oncology practitioners sometimes encounter patients with peripheral veins no longer able to accept an indwelling needle. A consequence of this is that medical oncologists will not be able to fi nd a reliable peripheral vein for administering the chemotherapeutic drugs that have a high potential for the induction of skin necrosis due to extravasation, such as vinorelbine, 5 docetaxel, paclitaxel, and amrubicin. For easy, safe and repeated venous access, totally implantable central venous access ports (TIAP), are widely used for the safe administration of chemotherapeutic drugs, blood transfusion, and parenteral nutrition in oncology; these devices can also help to overcome the problem of venous access in thoracic malignancies. 6 For the placement of a TIAP, catheter introduction through the subclavian vein to the superior vena cava (SVC) via the percutaneous approach, is the most common technique. 6, 7 However, this approach via the subclavian vein is associated with considerable complications, including pneu- 
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Background. For patients with a thoracic malignancy whose peripheral veins are not suitable for blood access for chemotherapy, we evaluated a totally implantable central venous access port, in which the port is implanted in the ulnar side of the arm and the catheter is introduced via the basilic vein into the superior vena cava (TIAP-BV). Methods. Twenty-fi ve patients (21 with lung cancer, 2 with malignant pleural mesothelioma, and 2 with thymoma) receiving TIAP-BV were included. Indications, surgical complications, and long-term complications were analyzed. Results. Indications for TIAP-BV were: chemotherapy (17 patients) and chemotherapy with parenteral nutrition (8 patients). The following surgical complications occurred: arrhythmia due to misplacement of the tip of catheter (1 patient); intraoperative conversion from the left to right arm (2 patients); and hematoma at the implantation site (1 patient). Short-term problems were: death 1 week after implantation without the use of TIAP-BV (2 patients). Long-term complications were: skin ulcer at the port site (1 patient); early removal of TIAP-BV because of port site infection (1 patient); catheter occlusion (1 patient); and venous thrombosis of basilic vein (2 patients). In the 22 patients who did not die early or have the device withdrawn early, the median duration of TIAP-BV use was 7 months (range, 1 to 20 months) without any break to the port system, leakage of drugs, or catheter-related infections. Conclusion. TIAP-BV can be employed for long-term use for chemotherapy and parenteral nutrition. However, a patient's expected prognosis and infectious disease status at the time of implantation surgery should be considered before the surgery proceeds. mothorax, hemothorax, injury of large vessels, and catheter pinch-off within the costoclavicular space. [6] [7] [8] The venous cut-down approach through the external jugular vein or cephalic vein has been reported to be one of a number of safe and easy alternatives. [9] [10] [11] In our department, prior to May 2006, we used the "TIAP via subclavian vein" approach. However, with this method, we experienced two cases of pinch-off syndrome of the implanted catheter. From June 2006, therefore, we have used the TIAP with the port implanted in the ulnar side of the arm, and the catheter introduced via the basilic vein to the SVC (TIAP-BV), using the Seldinger method. We made this switch due to the easier technique for implantation compared to the cut-down approach, and the avoidance of pinch-off of the catheter. Herein, we report our experiences and problems associated with the use of TIAP-BV.
Patients and methods

Patients
This was a retrospective study in 25 patients with thoracic malignancy; all patients had peripheral veins that were too fragile for practitioners to insert the usual indwelling needles for chemotherapy and/or fl uid administration. Between June 2006 and December 2007, these 25 patients underwent implantation of TIAP-BV in which the port was implanted in the ulnar side of the arm and the catheter was introduced via the basilic vein to the SVC, because of the fragility of their peripheral veins.
Implantation procedures of TIAP-BV
Implantation surgery was performed at the outpatient surgery unit of our hospital. Prior to the procedure, the direction of the basilic vein in the ulnar side of the arm (usually the left one) was established using radiographic or ultrasonographic guidance (Fig. 1 ). For left-handed patients, the right arm was selected. Under local anesthesia, an approximately 4-cm-long incision was made in the skin in the center of the ulnar side of arm and a subcutaneous pocket was prepared for the port body (Vital-Port MINI, IP-S5116, Cook Vascular Incorporated, Vandergrift, PA, USA; Fig. 2 ). The direction of the basilic vein was identifi ed again during the operation, under venography. According to the Seldinger method, the basilic vein was punctured with a 20-gauge indwelling needle under venograpy ( Fig. 3A B) ; and then a guidewire (Radifocus Guidewire M; RF-GA25123; Terumo, Tokyo, Japan) was introduced through the basilic vein (Fig. 3C) to the SVC. After dilating the puncture point of basilic vein with the introducer, a catheter was introduced along the guidewire and the tip of the catheter was placed in the SVC under radiographic guidance. The distal end of catheter was attached to the port body and the port was placed in the pocket. Flushing and fi lling with heparinized saline (100 IU/ml) was performed to verify the fl ow through the port system.
Use of TIAP-BV
If no incidences of hematoma, infection, or serous fl uid retention were identifi ed during a period of 3 to 7 days after 2 . A skin incision, approximately 4 cm long, and in a direction perpendicular to the running of the basilic vein, was made in the center of the ulnar side of the arm and a subcutaneous pocket was prepared for the port body implantation, then the TIAP-BV was used. The medical staff who used the TIAP-BV were all well-trained staff physicians of the Outpatient Oncology Unit or the Department of Respiratory Medicine, or staff surgeons of the Department of Thoracic Surgery at our institute. For puncture of the port, a 22-gauge noncoring needle (Coreless Needle Set; Nipro, Osaka, Japan) was used under aseptic conditions. After the TIAP-BV was used, it was fl ushed with 10 ml of heparinized saline (100 IU/ml). In patients with a temporary interruption of their chemotherapy, heparin fl ushing of the TIAP-BV was performed at intervals of approximately 4 weeks.
Evaluation
The reasons for the implantation of the TIAP-BV, stratifi ed by the number of regimens and cycles of chemotherapy before and after implantation, the operation time, complications of implantation surgery, usage of the TIAP-BV, and long-term complications / problems that occurred during the period from the implantation to April 2008, were all evaluated. Continuous variables were expressed as medians and the ranges are given.
Results
Patient demographics and baseline characteristics are presented in Table 1 . Of the 25 patients, 14 were male and 11 were female; they had a median age of 66 years (range, 39-79 years). Twenty-one patients had lung cancer, 2 had malignant pleural mesothelioma, and 2 had invasive thymoma.
The reasons for the use of TIAP-BV were: chemotherapy (17 patients) and chemotherapy with parenteral nutrition (8 patients). The median duration from the beginning of chemotherapy to implantation of TIAP-BV was 18 months (range, 0 to 84 months). The median number of chemotherapeutic regimens and cycles prior to TIAP-BV implantation was 2 (range, 0 to 11) and 8 (range, 0 to 46), respectively.
We planned initially to place the TIAP-BV on the left side in 24 patients, and on the right side in 1. A left-sided placement was successful in 22 of the 24 patients as planned; in the other 2 patients it became necessary to convert to the right because the left basilic vein was too fragile to insert a dilating introducer. The right-sided placement was also successful in the 1 patient in whom the intention had always been to opt for this side. The median time for the implantation was 37 min (range, 27 to 120 min). With respect to surgical complications (Table 2) , arrhythmia (frequent paroxysmal atrial contraction) occurred in one patient, probably as a consequence of the tip of the catheter touching the right atrium. After replacing the catheter tip on the SVC, the arrhythmia disappeared. In addition, a hematoma at the implanted site was reported in another patient; this resolved within 2 weeks. With respect to immediate mortality and morbidity problems (Table 2) , two patients (8%) died within 1 week of implantation, before a TIAP-BV had been used, because of rapid disease progression. In one other patient (4%), early removal of the TIAP-BV occurred, 8 days after implantation because of a port site infection, secondary to aspiration pneumonia with bacteremia due to methicillin-resistant Staphylococcus aureus.
With respect to long-term complications (Table 2) , venous thrombosis of the basilic vein in which the catheter was placed was observed in 2 patients (8%), approximately 3 weeks after implantation. These 2 patients received warfarin treatment and their TIAP-BV continued to be used without further complications, including pulmonary thromboembolism. Skin ulcer at the port site due to cutting of the skin with the needle during repeated puncture was observed in 1 patient (4%) after 7 months of use for chemotherapy and parenteral nutrition. Port occlusion was documented in 1 patient (4%) after 5 months of use for chemotherapy and parenteral nutrition. Among the 22 patients who were free of short-term complications (i.e., early death or early removal of the TIAP-BV), the TIAP-BV was used for a median of 7 months (range, 1 to 20 months) without damage to the port or catheter, leakage of drugs outside of the port system, pinch-off syndrome, or catheter-related infections. Of these 22 patients, 3 received none of their planned intravenous chemotherapy, but their TIAP-BVs were effectively used for parenteral nutrition or fl uid administration. In the other 19 patients, the median number of chemotherapeutic regimens and cycles after TIAP-BV implantation was 2 (range, 1 to 3) and 9 (range, 1 to 21), respectively. As of April 2008, 10 of the 25 patients (40%) had died since the placement of a TIAP-BV.
Discussion
In this study, we evaluated the experiences and the problems in the use of TIAP-BV in patients with thoracic malignancy, because we had been aware that there were very few reports on the use of TIAP in the Japanese population or regarding the implantation approach through the basilic vein with the Seldinger method.
In our patient series, the median number of chemotherapeutic regimens prior to TIAP-BV implantation was 2, with a median number of 8 cycles. Currently, there is no definitive indication for timing the employment of TIAP in the treatment of thoracic malignancies. At our institute, docetaxel-or vinorelbine-containing regimens are frequently used as second-line regimens for lung cancer and the peripheral veins of patients occasionally become fragile during second-line chemotherapy. In this situation, subsequent administration of third-line chemotherapy containing irinotecan, gemcitabine, or amrubicin through the peripheral veins carries a high risk of the development of skin ulcers and necrosis due to extravasation of drugs. Therefore, perhaps the beginning of a third-line regimen with potentially necrosis-inducing agents would be timely for the placement of TIAP.
With respect to surgical complications, we experienced two patients requiring intraoperative conversion from the left to right basilic vein. In both patients, we had ascertained a good fl ow through the left basilic vein immediately before surgery, using venography or ultrasonography. However, intraoperative fi ndings indicated that the walls of the basilic veins in these two patients were very fragile and considerable blood leakage occurred at the point of puncture for the wire guiding. Therefore, we decided to switch to the right arm. Conversion to the cut-down method involving the cephalic vein at a more central portion such as the delto-pectoral groove may be a good alternative 9 in these situations.
Arrhythmia and hematoma were also documented as surgical complications in our patient series. These would appear to be avoidable with careful catheter placement or hemostasis ascertainment.
Two early deaths were observed after the implantation of the TIAP-BV; both deaths were unrelated to TIAP-BV implantation, and were due to disease progression. Furthermore, in neither patient had the TIAP-BVs been used for chemotherapy or fl uid administration prior to death. Sadly, this means that for these two patients the implantation surgery had been in vain. This highlights the need for a careful evaluation of the prognosis of all potential candidates for TIAP-BV, prior to the procedure being started.
Catheter-related Infection is one important potential complication in the long-term management of TIAP. In the literature, infections related to totally implantable port systems occurred in 2.0% to 9.1% of patients. [12] [13] [14] [15] In our series, although no catheter-related infections were observed in the long-term management of TIAP-BV, one early portsite infection was documented; this was due to bacteremia from aspiration pneumonia, and occurred immediately after the implantation surgery. This patient was aspirationprone and easily developed bacteremia such as that causing this episode of catheter and port infection. Because hematogenous infection cannot be avoided with TIAP, even with the strictest antiseptic procedures being followed during the puncture for the port, severely compromised patients, including aspiration-prone patients or patients with an active infection, should not be considered for implantation. Thromboembolic complication is another important potential problem in the long-term management of TIAP. Catheter implantation itself carries a risk of venous thrombosis and cancer patients who need a TIAP have an increased risk of venous thrombosis. 6, 16 Although the detailed incidence of thromboembolic complications in TIAP-BV that we use is unclear, Kuriakose et al. 17 reported a higher incidence of arm venous thrombosis in patients with a peripherally placed port (11.4%) than in those with a chest port (4.8%). The incidence of arm venous thrombosis in our series (8%) is compatible with that of peripherally placed port. There are currently no defi nite recommendations or guidelines for the use of prophylactic anticoagulation therapy to prevent thromboembolic complications regarding TIAP. 6 Therefore, we feel that the prompt use of anticoagulation therapy after the occurrence of venous thrombosis is essential. 16 No complications regarding a breakdown of the port system or drug leaks were noted over the observation period of 1 to 20 months in our series. This is probably because the main users of TIAP-BV at our institute were all highly trained in the use of several types of TIAP systems, including TIAP-BV, and thereby mechanical damage to the port system could be avoided. Like other types of TIAP, TIAP-BV can provide safe venous access for long-term use when used appropriately by trained practitioners.
In conclusion, for patients with peripheral veins no longer able to accept an indwelling needle, TIAP-BV is safe and suitable for long-term use for chemotherapy, fl uid administration, and parenteral nutrition in patients with thoracic malignancy. Even from our limited experience, however, we can see that early death of patients and early removal after implantation are the most problematic issues in the application of TIAP-BV. Therefore, in considering the indications for the procedure, we should verify that a candidate for TIAP-PV has good performance status and suffi cient organ function to receive chemotherapy, and has a certain level of prognosis for which the chemotherapy would be effective, and has no active infection.
